

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **YAMADA, Yoshiji, et al.**

Group Art Unit: **Not yet assigned**

Serial No.: **10/524,021**

Examiner: **Not yet assigned**

Filed: **February 9, 2005**

For: **METHOD OF DIAGNOSING RISK OF RESTENOSIS AFTER
CORONARY ANGIOPLASTY**

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 CFR 1.97(b)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

August 23, 2005

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-1449. One copy of each of these documents is attached, together with a copy of a Supplementary European Search Report which was issued in the proceedings of a corresponding foreign application.


No fee or certification is required in connection with this Information Disclosure Statement, since it is being submitted prior to the issuance of a first official action on the merits or expiration of the three month period following the filing date or the entry of the national stage of the above-captioned application.

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-1449 be made of record therein and appear on the first page of any patent to issue therefrom.

The Commissioner is authorized to charge our Deposit Account No. 01-2340 for any fee which is deemed by the Patent and Trademark Office to be required to effect consideration of this statement.

Respectfully submitted,

ARMSTRONG, KRATZ, QUINTOS,
HANSON & BROOKS, LLP


James E. Armstrong, IV
Attorney for Applicant
Reg. No. 42,266


JAM/nrp
Atty. Docket No. **050070**
Suite 1000
1725 K Street, N.W.
Washington, D.C. 20006
(202) 659-2930



23850

PATENT TRADEMARK OFFICE

Enclosures: Supplementary European Search Report
PTO-1449
References (6)



INFORMATION DISCLOSURE CITATION PTO-1449	Atty. Docket No. 050070	Serial No. 10/524,021
	Applicant(s): YAMADA, Yoshiji, et al.	
	Filing Date: February 9, 2005	Group Art Unit:

U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Name	Date	Class	Subclass	Filing Date (If appropriate)
_____	AA					
_____	AB					

FOREIGN PATENT DOCUMENTS

Document No.	Date	Country	Translation (Yes or No)
_____ AC			

OTHER DOCUMENTS

_____	AD	NASSAR BASSAM A et al: "Relation of genetic polymorphism of apolipoprotein E, angiotensin converging enzyme, apolipoprotein B-100, and glycoprotein IIIa and early-onset coronary heart disease", CLINICAL BIOCHEMISTRY, vol. 32, no. 4, June 1999, pages 275-282.		
_____	AE	BRSCIC ELVIS et al: "Acute myocardial infarction in young adults: Prognostic role of angiotensin-converting enzyme, angiotensin II type I receptor, apolipoprotein E, endothelial constitutive nitric oxide synthase, and glycoprotein IIIa genetic polymorphism at medium-term follow-up", AMERICAN HEART JOURNAL, vol. 139, no 6., June 2000, pages 979-984.		
_____	AF	REINER A P et al: "Platelet glycoprotein gene polymorphism and risk of thrombosis: facts and fancies.", REVIEWS IN CLINICAL AND EXPERIMENTAL HEMATOLOGY, September 2001, vol. 5, no. 3, pages 262-287.		
_____	AG	DALEY G Q et al: "The heart SNPs a beat: polymorphism in candidate genes for cardiovascular disease.", TRENDS IN CARDIOVASCULAR MEDICINE, February 2001, vol. 11, no. 2, pages 60-66.		
_____	AH	YAMADA YOSHIJI et al: "Prediction of the risk of myocardial infarction from polymorphism in candidate genes.", NEW ENGLAND JOURNAL OF MEDICINE, December 2002, vol. 347, no. 24, pages 1916-1923.		
_____	AI	IZAWA HIDEO et al: "Prediction of genetic risk for hypertension", HYPERTENSION (BALTIMORE), May 2003, vol. 41, no. 5, pages 1035-1040.		
<table border="1"> <tr> <td>Examiner</td> <td>Date Considered</td> </tr> </table>			Examiner	Date Considered
Examiner	Date Considered			